PF-00446687

PF-00446687 is a drug that was developed by Pfizer for the treatment of Type 2 diabetes. It functions as a glucokinase activator, which is a novel mechanism of action that is currently under investigation for potential therapeutic use in diabetes treatment.

Mechanism of Action

PF-00446687 works by activating the enzyme glucokinase, which plays a key role in the regulation of carbohydrate metabolism. By increasing the activity of this enzyme, PF-00446687 enhances the conversion of glucose to glucose-6-phosphate, thereby promoting the uptake and utilization of glucose by the body's cells and reducing blood glucose levels.

Clinical Trials

In clinical trials, PF-00446687 has shown promise as a treatment for type 2 diabetes. In a Phase 2 trial, the drug was found to significantly reduce HbA1c levels, a key marker of long-term blood glucose control, in patients with type 2 diabetes. However, further research is needed to fully evaluate the drug's efficacy and safety profile.

Potential Side Effects

As with any drug, PF-00446687 may cause side effects. In clinical trials, the most common side effects reported were hypoglycemia (low blood sugar), nausea, and diarrhea. Patients should be monitored closely for these and other potential side effects while taking PF-00446687.

See Also

• Glucokinase
• Type 2 diabetes
• Pfizer

References

PF-00446687 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia